Indication intelligence, analysis and sector perception

Biostage (BSTG) Chronicles: Another Q reporting MISS, why another missed date filing?

May 21, 2021 12:15pm

BSTG “could NOT complete the filing of its Q1 reporting”

Do investors think – something continues to be amiss? Wonder if they’re “cash broke”? <read more>

Biostage (BSTG) is trading flat at $1.30 after closing Thursday flat at 41.30 with 1 share traded, Wednesday’s +$0.16 to $1.30 with 930 shares traded, Tuesday’s -$0.16 to $1.13 with 250 shares traded, Monday’s +$0.15 to $1.30 with 2,642 shares traded and last Friday’s flat with 54 shares traded.

Biostage (BSTG) SEC filing: “could not complete the filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2021 due to disruptions in staffing. This in turn, delayed the Company’s ability to obtain and compile the information required to be included in the Company's Form 10-Q, which delay could not be eliminated by the Company without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Company will file its Form 10-Q no later than the fifth calendar day following the prescribed due date”. Do investors think – something continues to be amiss? Their interim financial officed did get Q4 and FY20 “umbers” out, is there an issue of “cash position” behind the “hide” or late-filing?

Question#1: WHY is BSTG NOT filing the Q1 earnings’ report? Their interim financial officer, Peter A. Pellegrino Jr. of Point Providence Consulting has been appointed since 4/8/21 and still was NOT able to produce a Q1 report? Are there other issues – like being out of cash or soon to be?

Question#2: What is there to invest in, an IND a year old with NO clinical trial, NO management, barely any employees and huge overhead (buildings etc.) expense with WHAT capacity to finance? With only $1 million left (12/31/20) in the “till” WHAT is the runway with a “spend” and “net cash in operations of $4 million during the year ended 12/ 31/20”. Don’t forget the PPP loan remaining as DEBT ($0.4 million).

Question#3; WHO or WHAT “entity” is promoting and pumping the share volume to stimulate the pricing as the stock barely trades on its own?

MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

3 hours 18 min ago
RegMed Investors’ (RMi) pre-open: expectation versus reality

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.